A Special Master has ordered that five more Valsartan lawsuits be prepared for a second round of potential bellwether trials, to further test claims that the recalled blood pressure drugs caused users to develop cancer.
Lawsuit claims AngioDynamics knew there were fracture problems and risks from its Vaxcel product for years, but failed to change the chemo port’s construction or provide adequate warnings to the medical community or patients.
A federal judge has scheduled a hearing in May to review evidence linking Ozempic and similar drugs to gastrointestinal problems, such as gastroparesis and intestinal obstruction.
